ICD-inducing therapies are characterized by their capacity to enhance APC activation, priming of tumor-specific CD8+ T cells, and recruiting immune cells via the production of tumor antigens PAMPs and/or DAMPs, including calreticulin (CRT), heat shock proteins (HSPs) 70 and 90, and high-mobility group box 1 (HMGB1) (Figure 7) [127,128]. This evidence concerns the gene CALR and neoplasm.